Psilocybin Assisted Therapy

We support you in the application process to access Psilocybin Assisted Therapy for treatment-resistant mental health concerns.

Psilocybin Assisted Therapy is an option that can be explored when other modalities such as antidepressants or talk-therapy don’t work, and has been used as an adjunct to therapy since the 1970’s. While the safety and effectiveness of Psilocybin in therapy is still under investigation, Health Canada allows physicians to request access for unique cases of treatment-resistant mental health concerns, specifically depression and end-of-life.

Psilocybin & its potential benefits

Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, often known as “magic” or “psychedelic” mushrooms. These mushrooms have been used in spiritual and ritual practices by indigenous cultures for centuries. After ingestion, the body metabolizes psilocybin, transforming it into psilocin. 

This converted compound, psilocin, interacts with the brain’s receptors, causing the altered states of consciousness associated with psilocybin ingestion. Through its unique properties, psilocybin can open the door to deep introspection, heightened sensory perception, and a profound sense of interconnectedness. In therapeutic settings, psilocybin helps to facilitate experiences that promote self-reflection, emotional exploration, and personal growth. Research suggests that psilocybin-assisted therapy may have long-lasting positive effects on mood, well-being, and can cause a renewed sense of meaning and purpose in life

Psilocybin for Psilocybin-Assisted Therapy

Ready to get started?

As you book an information call, we invite you to review these important considerations. They play a role in determining your eligibility for treatment. Your attention to these questions will help us better understand your needs and supports for your journey.

Applying to access Psilocybin Assisted Therapy

Clients can apply to access this unique mental health treatment through a specific application process, even though this treatment has not yet received official approval. This application process provides a unique opportunity for individuals dealing with challenging mental health conditions.

Recognizing the complexities and challenges of navigating the application process, ATMA CENA, alongside healthcare professionals, facilitates the entire application process on behalf of the clients. This includes assistance from application submission to the delivery of Psilocybin Assisted Therapy, simplifying the journey toward accessing this potentially life-changing treatment. Our dedicated effort aims to bring relief and hope to those seeking alternative solutions in their healthcare journey, making innovative therapeutic options more accessible to those in need.

A $300 non-refundable deposit is required for all ATMA CENA treatment programs, which will be applied toward your treatment.

Our Psilocybin Assisted Therapy program

Health Canada Application Fee

To gain access to psilocybin, special approval from Health Canada is required. We can facilitate this application for you. Deposit breakdown: $300 non-refundable deposit & $200 application fee.

This application fee is non-refundable.

$500 CAD

First Dose of Psilocybin

Each dose of psilocybin is paired with therapy. This process includes a psychiatric assessment & clinical assessment. 

A medicine session takes 6 hours and requires at least 10 hours of additional clinical and therapy support.

$2,995 CAD

Second Dose of Psilocybin

A second dose may be administered as needed, paired with therapy and assessments.

$2,395 CAD

Schedule a free Information
Call to get started

Disclaimer

Psilocybin has not received approval from Health Canada or the Food and Drug Administration for treating any mental health conditions. This page offers information strictly for educational purposes and does not comprehensively cover the current research on psychedelic treatments, including their effectiveness, contraindications, risks, side effects, or other relevant details. For further information, please refer to our Disclaimers in our Terms of Use.

Join our community newsletter